Ignite Creation Date:
2025-12-25 @ 12:15 AM
Ignite Modification Date:
2026-05-20 @ 2:07 AM
Study NCT ID:
NCT01337258
Status:
COMPLETED
Last Update Posted:
2017-05-30
First Post:
2010-03-04
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Economic Analyses of the REDUCE Trial
Sponsor:
GlaxoSmithKline
Organization:
Study Overview
Official Title:
Economic Analyses Alongside the REDUCE Clinical Trial
Status:
COMPLETED
Status Verified Date:
2017-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of this project is to conduct a retrospective economic analysis of the use of dutasteride for the prevention of prostate cancer based on data from the REDUCE clinical trial. REDUCE is a 4-year, phase 3, randomized, double-blind, parallel assignment clinical trial of the use of dutasteride compared with no chemopreventive treatment.
The REDUCE trial was a four-year, international, multicenter, randomized, double-blind, placebo-controlled, parallel group study. There were 790 investigators in 42 countries.
The REDUCE trial was a four-year, international, multicenter, randomized, double-blind, placebo-controlled, parallel group study. There were 790 investigators in 42 countries.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: